---
layout: post
title: "Nonclinical Testing of Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases; Draft Guidance for Sponsor-Investigators; Availability"
date: 2026-02-05 19:09:25 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2021-08675
original_published: 2021-04-27 00:00:00 +0000
significance: 8.00
---

# Nonclinical Testing of Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases; Draft Guidance for Sponsor-Investigators; Availability

**Published:** February 05, 2026 19:09 UTC
**Source:** Federal Register
**Original Published:** April 27, 2021 00:00 UTC
**Document Number:** 2021-08675

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Nonclinical Testing of Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases." FDA is publishing this draft guidance to help sponsor-investigators (hereafter referred to as sponsors) with developing the nonclinical information that FDA recommends to support an investigational new drug application (IND) for certain individualized antisense oligonucleotide (ASO) drug products. ASO drug products that are the focus of this draft guidance are those being developed to treat rapidly progressing, severely debilitating or life-threatening (SDLT) disease attributable to a unique genetic variant or variants that may be amenable to RNA- directed treatment.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2021/04/27/2021-08675/nonclinical-testing-of-individualized-antisense-oligonucleotide-drug-products-for-severely)
- API: https://www.federalregister.gov/api/v1/documents/2021-08675

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
